Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
3.9
Journals
Biomedicines
Special Issues
New Advances in Precision Medicine for Pituitary Tumors
share announcement

New Advances in Precision Medicine for Pituitary Tumors

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: closed (31 August 2022) | Viewed by 3236

Special Issue Editor

Dr. Cheol Ryong Ku

E-Mail Website
Guest Editor
Department of Internal Medicine, Institute of Endocrine Research, Yonsei University College of Medicine, Seoul 03722, Korea
Interests: novel therapeutic target for pituitary tumors; biomarkers associated with therapeutic responsiveness of pituitary tumors; novel therapeutic target for metabolic syndrome based on bariatric surgery

Special Issue Information

Dear Colleagues,

Pituitary tumors are rare conditions which can cause the hormonal abnormality and the mass effect such as visual field defect. The frequency of this disease increases as the age of individual increases, and it can cause headache or visual field defect, together with hormonal dysfunctions.

For treatment of pituitary adenomas, there are three options: surgical resection, medical therapeutics, and radiotherapy. Because the clinical approach is moving toward value-based reimbursements, analyses for treatment cost-effectiveness and efficacies are required to define the optimal control of disease progression for individual patients. Late diagnosis and management are a hurdle that necessitates the initiation of precision therapy, or customization of treatment to specific patients, in everyday practice. Furthermore, cases of resistance to surgical or medical treatment require an integration of clinical and molecular predictors to aid in selecting the best tailored treatment. Simultaneous consideration of all predictors, such as the patient’s gender, age, preoperative hormonal levels, tumor size, somatostatin and dopamine receptor sensitivity and expression, and signaling pathway disruption, among others, plays a role in improving remission rates.

In this Special Issue, we publish reviews and original research that provide new insights into novel therapeutic targets, biomarkers associated with treatment responsiveness, and predictors of prognosis of pituitary tumors. Articles about multi-omics approaches will be particularly welcomed.

Dr. Cheol Ryong Ku
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pituitary tumor
  • prolactinoma
  • acromegaly
  • cushing’s disease
  • nonfunctioning pituitary tumor
  • TSH secreting pituitary tumor
  • therapeutic target for pituitary tumor
  • biomarkers associated with treatment responsiveness of pituitary tumors
  • precision medicine for pituitary tumor
  • genomics of pituitary tumor
  • radiomics of pituitary tumor

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

11 pages, 262 KiB  
Article
IL-10 Gene Rs1800871, Rs1800872, and Rs1800896 Polymorphisms and IL-10 Serum Levels Association with Pituitary Adenoma
by Migle Palivonaite, Greta Gedvilaite, Brigita Glebauskiene, Loresa Kriauciuniene, Vita Rovite and Rasa Liutkeviciene
Biomedicines 2022, 10(8), 1921; https://doi.org/10.3390/biomedicines10081921 - 8 Aug 2022
Cited by 2 | Viewed by 1455
Abstract
The aim and objective of this study is to determine the association between the rs1800871, rs1800872, and rs1800896 polymorphisms of the gene IL-10 and the serum levels of IL-10 in patients with pituitary adenoma. Methods: Data from 106 patients with pituitary adenoma and [...] Read more.
The aim and objective of this study is to determine the association between the rs1800871, rs1800872, and rs1800896 polymorphisms of the gene IL-10 and the serum levels of IL-10 in patients with pituitary adenoma. Methods: Data from 106 patients with pituitary adenoma and 192 control patients were used for the study. DNA was isolated from peripheral blood using the salt precipitation method. The samples were genotyped in real-time using the polymerase chain reaction method. IL-10 serum levels were evaluated using an ELISA kit. The data obtained were systematized using the computer program IBM SPSS Statistics. Results: The AG genotype of IL-10 rs1800871 was statistically significantly lower in the inactive PA group than in the control group (22.7% vs. 40.6%, p = 0.027). The TG genotype of IL-10 rs1800872 was also statistically significantly lower in the inactive PA group than in the control group (22.7% vs. 40.6%, p = 0.027). A binary logistic regression analysis of the polymorphisms in the IL-10 gene in PA and control groups based on the pituitary adenoma activity showed that the AG genotype of IL-10 rs1800871 increased the chance of inactive PA by 2.2-fold in codominant (OR: 2.272, CI: 1.048–4.925, p = 0.038) and overdominant (OR: 2.326, CI: 1.086–4.982, p = 0.030) models. Moreover, the TG genotype of IL-10 rs1800872 increased the probability of inactive PA by 2.2-fold in codominant (OR: 2.272, CI: 1.048–4.925, p = 0.038) and overdominant (OR: 2.326, CI: 1.086–4.982, p = 0.030) models. The association of the IL-10 polymorphisms with PA invasiveness and recurrence in PA and control groups did not yield statistically significant results. Conclusions: IL-10 rs1800871 and IL-10 rs1800872 may be associated with the development of inactive PA. Full article
(This article belongs to the Special Issue New Advances in Precision Medicine for Pituitary Tumors)

Other

Jump to: Research

8 pages, 2009 KiB  
Case Report
DNA Methylation Profiling in Rare Sellar Tumors
by Kyla Wright, Kristyn Galbraith, Matija Snuderl and Nidhi Agrawal
Biomedicines 2022, 10(9), 2225; https://doi.org/10.3390/biomedicines10092225 - 8 Sep 2022
Viewed by 1293
Abstract
The histologic diagnosis of sellar masses can be challenging, particularly in rare neoplasms and tumors without definitive biomarkers. Moreover, there is significant inter-observer variability in the histopathological diagnosis of many tumors of the CNS, and some rare tumors risk being misclassified. DNA methylation [...] Read more.
The histologic diagnosis of sellar masses can be challenging, particularly in rare neoplasms and tumors without definitive biomarkers. Moreover, there is significant inter-observer variability in the histopathological diagnosis of many tumors of the CNS, and some rare tumors risk being misclassified. DNA methylation has recently emerged as a useful diagnostic tool. To illustrate the clinical utility of machine-learning-based DNA methylation classifiers, we report a rare case of primary sellar esthesioneuroblastoma histologically mimicking a non-functioning pituitary adenoma. The patient had multiple recurrences, and the resected specimens had unusual histopathology. A portion of the resected sellar lesion was profiled using clinically validated whole-genome DNA methylation and classification. DNA was extracted from the tissue, hybridized on DNA methylation chips, and analyzed using a clinically validated classifier. DNA methylation profiling of the lesion showed that the tumor classified best with the esthesioneuroblastoma reference cohort. This case highlights the difficulty in diagnosing atypical sellar lesions by standard histopathological methods. However, when phenotypic analyses were nonconclusive, DNA methylation profiling resulted in a change in diagnosis. We discuss the growing role of DNA methylation profiling in the classification and diagnosis of CNS tumors, finding that utilization of DNA methylation studies in cases of atypical presentation or diagnostic uncertainty may improve diagnostic accuracy with therapeutic and prognostic implications. Full article
(This article belongs to the Special Issue New Advances in Precision Medicine for Pituitary Tumors)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop